These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34800352)

  • 21. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
    Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
    J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 4-Methylumbelliferone induces antitumor effects independently of hyaluronan synthesis inhibition in human acute leukemia cell lines.
    Díaz M; Pibuel M; Paglilla N; Poodts D; Álvarez E; Papademetrio DL; Hajos SE; Lompardía SL
    Life Sci; 2021 Dec; 287():120065. PubMed ID: 34678263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.
    Ningarhari M; Caruso S; Hirsch TZ; Bayard Q; Franconi A; Védie AL; Noblet B; Blanc JF; Amaddeo G; Ganne N; Ziol M; Paradis V; Guettier C; Calderaro J; Morcrette G; Kim Y; MacLeod AR; Nault JC; Rebouissou S; Zucman-Rossi J
    J Hepatol; 2021 May; 74(5):1155-1166. PubMed ID: 33338512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells.
    Nagase H; Kudo D; Suto A; Yoshida E; Suto S; Negishi M; Kakizaki I; Hakamada K
    Pancreas; 2017 Feb; 46(2):190-197. PubMed ID: 27846148
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3.
    Kultti A; Pasonen-Seppänen S; Jauhiainen M; Rilla KJ; Kärnä R; Pyöriä E; Tammi RH; Tammi MI
    Exp Cell Res; 2009 Jul; 315(11):1914-23. PubMed ID: 19285976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of pro-angiogenic and prometastatic factors in murine liver fibrosis.
    Kornek M; Raskopf E; Tolba R; Becker U; Klöckner M; Sauerbruch T; Schmitz V
    Liver Int; 2008 Apr; 28(4):509-18. PubMed ID: 18339078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
    Ke MY; Xu T; Fang Y; Ye YP; Li ZJ; Ren FG; Lu SY; Zhang XF; Wu RQ; Lv Y; Dong J
    Cancer Lett; 2021 Aug; 513():14-25. PubMed ID: 33992711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo.
    Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z
    Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease.
    Chappell G; Silva GO; Uehara T; Pogribny IP; Rusyn I
    Cancer Med; 2016 Mar; 5(3):574-85. PubMed ID: 26778414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma.
    Tarocchi M; Polvani S; Peired AJ; Marroncini G; Calamante M; Ceni E; Rhodes D; Mello T; Pieraccini G; Quattrone A; Luchinat C; Galli A
    J Hepatol; 2014 Nov; 61(5):1064-72. PubMed ID: 24862448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.
    Komoll RM; Hu Q; Olarewaju O; von Döhlen L; Yuan Q; Xie Y; Tsay HC; Daon J; Qin R; Manns MP; Sharma AD; Goga A; Ott M; Balakrishnan A
    J Hepatol; 2021 Jan; 74(1):122-134. PubMed ID: 32738449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved method increases sensitivity for circulating hepatocellular carcinoma cells.
    Liu HY; Qian HH; Zhang XF; Li J; Yang X; Sun B; Ma JY; Chen L; Yin ZF
    World J Gastroenterol; 2015 Mar; 21(10):2918-25. PubMed ID: 25780289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma.
    Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh S; Singh P; Guleria A; Saha S; Saraf SA
    Mol Pharm; 2021 Mar; 18(3):1102-1120. PubMed ID: 33356314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
    Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
    Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
    Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
    Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
    Miyauchi Y; Yasuchika K; Fukumitsu K; Ishii T; Ogiso S; Minami T; Kojima H; Yamaoka R; Katayama H; Kawai T; Yoshitoshi-Uebayashi EY; Kita S; Yasuda K; Sasaki N; Uemoto S
    Sci Rep; 2017 Aug; 7(1):9827. PubMed ID: 28851916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
    Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
    J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma.
    Yang Z; Zhuang L; Szatmary P; Wen L; Sun H; Lu Y; Xu Q; Chen X
    Int J Med Sci; 2015; 12(3):256-63. PubMed ID: 25798051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.